Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Benjamin D, Leibowitz"'
Autor:
Benjamin D. Leibowitz, Bonnie V. Dougherty, Joshua S. K. Bell, Joshuah Kapilivsky, Jackson Michuda, Andrew J. Sedgewick, Wesley A. Munson, Tushar A. Chandra, Jonathan R. Dry, Nike Beaubier, Catherine Igartua, Timothy Taxter
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-17 (2022)
Abstract Background With the introduction of DNA-damaging therapies into standard of care cancer treatment, there is a growing need for predictive diagnostics assessing homologous recombination deficiency (HRD) status across tumor types. Following th
Externí odkaz:
https://doaj.org/article/dabd382b971d4f07ac2e0b21a3f9c4c3
Autor:
Brian M. Larsen, Madhavi Kannan, Lee F. Langer, Benjamin D. Leibowitz, Aicha Bentaieb, Andrea Cancino, Igor Dolgalev, Bridgette E. Drummond, Jonathan R. Dry, Chi-Sing Ho, Gaurav Khullar, Benjamin A. Krantz, Brandon Mapes, Kelly E. McKinnon, Jessica Metti, Jason F. Perera, Tim A. Rand, Veronica Sanchez-Freire, Jenna M. Shaxted, Michelle M. Stein, Michael A. Streit, Yi-Hung Carol Tan, Yilin Zhang, Ende Zhao, Jagadish Venkataraman, Martin C. Stumpe, Jeffrey A. Borgia, Ashiq Masood, Daniel V.T. Catenacci, Jeremy V. Mathews, Demirkan B. Gursel, Jian-Jun Wei, Theodore H. Welling, Diane M. Simeone, Kevin P. White, Aly A. Khan, Catherine Igartua, Ameen A. Salahudeen
Publikováno v:
Cell Reports, Vol 36, Iss 4, Pp 109429- (2021)
Summary: Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer biology and develop novel precision medicine therapeutics. However, utilizing TOs for systems-biology-based approaches has been limited by a lack of s
Externí odkaz:
https://doaj.org/article/9e05120e2cf8481abf4978520140395c
Autor:
Gary A. Palmer, Caroline G. Epstein, Michael D. Axelson, Michael E. Salazar, Matthew Kase, Martin C. Stumpe, Calvin McCarter, Ashraf T. Hafez, Joyce O'Shaughnessy, Alexandria M. Bobe, Benjamin D. Leibowitz, Ameen A. Salahudeen, Joshua S.K. Bell, Nike Beaubier, Catherine Igartua, Robert Huether, Mark D. Pegram, Louis E. Fernandes, Ruth A. Pe Benito, Sarah Sammons
Publikováno v:
Clinical Breast Cancer. 21:e340-e361
Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc2b8c3d39d5c448164e102fff4a8751
https://doi.org/10.1016/j.clbc.2020.11.012
https://doi.org/10.1016/j.clbc.2020.11.012
Autor:
Nike Beaubier, Gini F. Fleming, Anna Woodard, Padma Sheila Rajagopal, Yonglan Zheng, Galina Khramtsova, Abiola Ibraheem, Elisabeth Sveen, Benjamin D. Leibowitz, Olufunmilayo I. Olopade, Minoru Miyashita, Rita Nanda, Nora Jaskowiak, Kevin P. White, Jean Baptiste Reynier, Joshua S.K. Bell, Toshio F. Yoshimatsu, Dezheng Huo, Fang Liu
Publikováno v:
Cancer Research. 81:SS1-04
Background: Breast cancer demonstrates heterogeneity in biological features, and the therapeutic strategy depends on tumor subtype. African-Ancestry (AA) patients experience a disproportionally high rate of triple negative breast cancer (TNBC) and wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::033b9270706e68c552896dfada6f9879
https://doi.org/10.1158/1538-7445.sabcs20-ss1-04
https://doi.org/10.1158/1538-7445.sabcs20-ss1-04
Autor:
Benjamin D. Leibowitz, Nike Beaubier, Jason Perera, Ariane Lozac’hmeur, Ameen A. Salahudeen, Aly A. Khan, Timothy Taxter, Kaanan P. Shah, Derick Hoskinson, Emily Kudalkar, Jackson Michuda, Jerod Parsons, Alexandria M. Bobe, Denise Lau, Stephen Bush, Robert Huether, Alan L. Chang, Wei Zhu, Robert Tell, Kevin P. White, Martin Bontrager, Catherine Igartua
Publikováno v:
Nature Biotechnology. 37:1351-1360
Genomic analysis of paired tumor–normal samples and clinical data can be used to match patients to cancer therapies or clinical trials. We analyzed 500 patient samples across diverse tumor types using the Tempus xT platform by DNA-seq, RNA-seq and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75e7c20ce62d0bedf60d781e2d0ba5c0
https://doi.org/10.1038/s41587-019-0259-z
https://doi.org/10.1038/s41587-019-0259-z
Autor:
Theodore H. Welling, Diane M. Simeone, Benjamin A. Krantz, Aïcha BenTaieb, Andrea Cancino, Chi Sing Ho, Jeffrey A. Borgia, Jeremy V. Mathews, Brandon Mapes, Michael A. Streit, Jian Jun Wei, Ameen A. Salahudeen, Bridgette E. Drummond, Veronica Sanchez-Freire, Martin C. Stumpe, Aly A. Khan, Tim A. Rand, Ende Zhao, Kelly E. McKinnon, Benjamin D. Leibowitz, Demirkan B. Gursel, Madhavi Kannan, Jagadish Venkataraman, Yi-Hung Carol Tan, Brian M. Larsen, Jonathan R. Dry, Gaurav Khullar, Jenna M. Shaxted, Catherine Igartua, Kevin P. White, Daniel V.T. Catenacci, Ashiq Masood, Jason Perera, Jessica Metti, Michelle M. Stein, Igor Dolgalev, Lee F. Langer, Yilin Zhang
Publikováno v:
Cell Reports, Vol 36, Iss 4, Pp 109429-(2021)
Summary: Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer biology and develop novel precision medicine therapeutics. However, utilizing TOs for systems-biology-based approaches has been limited by a lack of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85ee6070df11c2b91a956a81ab264980
https://pubmed.ncbi.nlm.nih.gov/34320344
https://pubmed.ncbi.nlm.nih.gov/34320344
Autor:
Nike Beaubier, Matthew Kase, Ameen A. Salahudeen, Martin C. Stumpe, Louis E. Fernandes, Ruth A. Pe Benito, Joshua S.K. Bell, Alexandria M. Bobe, Caroline G. Epstein, Michael D. Axelson, Gary A. Palmer, Catherine Igartua, Calvin McCarter, Michael E. Salazar, Joyce O'Shaughnessy, Robert Huether, Mark D. Pegram, Sarah Sammons, Ashraf T. Hafez, Benjamin D. Leibowitz
INTRODUCTIONWe performed a retrospective analysis of longitudinal real-world data (RWD) from breast cancer patients to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the val
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a83cb92f2552fe3ec5cabdebe607431
https://doi.org/10.1101/2020.08.07.20168401
https://doi.org/10.1101/2020.08.07.20168401
Autor:
Jason Zhu, Sherif Mohamed El-Refai, Elizabeth Mauer, Benjamin D. Leibowitz, Landon Carter Brown, Claud Grigg, James T Kearns, Justin T. Matulay, Peter E Clark, Derek Raghavan, Earle F Burgess
Publikováno v:
Journal of Clinical Oncology. 40:151-151
151 Background: The use of PARP inhibitors (PARPi) may trigger synthetic lethality of tumor cells in the context of deficient homologous recombination repair (HRR). Approximately 10-20% of patients with prostate cancer harbor mutations in the HRR pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::832ef2deae87f2f6b4809f619ab597ea
https://doi.org/10.1200/jco.2022.40.6_suppl.151
https://doi.org/10.1200/jco.2022.40.6_suppl.151
Autor:
Hitendra Patel, Alex Barrett, Elizabeth Mauer, Shumei Kato, Benjamin D. Leibowitz, Aatur D. Singhi, Milind M. Javle, Andrew M. Lowy
Publikováno v:
Journal of Clinical Oncology. 40:609-609
609 Background: Homologous recombination repair (HRR) is critical for limiting DNA damage arising from double strand breaks. Disrupting HRR has emerged as a therapeutic strategy in pancreatic cancer given the development of PARP inhibitors that can s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a0b7517614dcf4dbfe15e7e88b18e90
https://doi.org/10.1200/jco.2022.40.4_suppl.609
https://doi.org/10.1200/jco.2022.40.4_suppl.609
Autor:
Abiola Ibraheem, Nike Beaubier, Jean Baptiste Reynier, Anna Woodard, Rita Nanda, Elisabeth Sveen, Galina Khramtsova, Minoru Miyashita, Dezheng Huo, Padma Sheila Rajagopal, Kevin P. White, Masaya Hattori, Olufunmilayo I. Olopade, Joshua S.K. Bell, Fang Liu, Toshio F. Yoshimatsu, Yonglan Zheng, Nora Jaskowiak, Benjamin D. Leibowitz, Gini F. Fleming
Publikováno v:
Cancer Research. 81:PD7-06
Background: In patients with early breast cancer, neoadjuvant therapy is widely performed as standard of care. While the molecular targeting strategy makes progress in HER2 positive breast cancer, the optimal regimens for ER+/HER2- breast cancer (BC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::652c206e6232a7bde771b5d7ed97bf47
https://doi.org/10.1158/1538-7445.sabcs20-pd7-06
https://doi.org/10.1158/1538-7445.sabcs20-pd7-06